Innovations In Clinical Neuroscience

MAR-APR 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/822795

Contents of this Issue

Navigation

Page 13 of 45

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 3 – 4 , M A R C H – A P R I L 2 0 1 7 ] 14 he exhibited delay in speech, difficulty concentrating, and signs of cognitive impairment. His pediatric neurologist diagnosed him with ASD and pediatric acute-onset neuropsychiatric syndrome. The patient also suffered from respiratory tract infections frequently. Gourmet insertion (B/L) also took place at the age of five years. He suffered from Lyme's disease syndrome in 2007 for which he underwent the complete Lyme's treatment protocol with hyperbaric oxygen therapy (HBOT). He also suffered from heavy metal toxicity, which was treated with ethylenediaminetetraacetic acid (EDTA), dimercapto propanesulfonic acid (DMPS), and HBOT. FIGURE 1, CASE 1. Single-photon emission computed tomography scan before and after human embryonic stem cell therapy therapy—grey: normal; red, pink, white: above normal; green, light blue, dark blue, black: hypoperfused regions FIGURE 2, CASE 2. Single-photon emission computed tomography scan before and after human embryonic stem cell therapy therapy—grey: normal; red, pink, white: above normal; green, light blue, dark blue, black: hypoperfused regions

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2017